AI-guided generation of novel GUCY2C-targeting T-cell engagers for the treatment of colorectal cancer

被引：0
|
作者：
Tian, Liang
Hou, Jinxiu
Su, Chenpeng
Xu, Xiaoou
Chen, Xiaoqian
Liu, Dandan
Tian, Jiyuan
Shen, Rui
Pan, Yi
Yuan, Yuan
Dong, Lisha
Gu, Tingting
Peng, Jian
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6721
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6721
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cytotoxic T Cells Expressing GUCY2C-Specific Chimeric Antigen Receptor as Targeted Therapy for Metastatic Colorectal Cancer
    Magee, Michael S.
    Snook, Adam E.
    Hersperger, Adam R.
    Marszalowicz, Glen
    Waldman, Scott A.
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 726 - 726
  • [32] Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer
    Ducoin, Kathleen
    Oger, Romain
    Mutala, Linda Bilonda
    Deleine, Cecile
    Jouand, Nicolas
    Desfrancois, Juliette
    Podevin, Juliette
    Duchalais, Emilie
    Cruard, Jonathan
    Benlalam, Houssem
    Labarriere, Nathalie
    Bossard, Celine
    Jarry, Anne
    Gervois-Segain, Nadine
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [33] LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager
    Corrales, Leticia
    Hipp, Susanne
    Martin, Katharina
    Sabarth, Nicolas
    Tirapu, Inigo
    Fuchs, Klaus
    Thaler, Barbara
    Walterskirchen, Christian
    Bauer, Kathrin
    Fabits, Markus
    Bergmann, Michael
    Binder, Carina
    Chetta, Paolo ML.
    Vogt, Anne B.
    Adam, Paul J.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [34] Phase I Study of GUCY2C CAR-T Therapy IM96 in Metastatic Colorectal Cancer Patients
    Qi, Changsong
    Liu, Chang
    Li, Jian
    Gong, Jifang
    Wang, Xicheng
    Wang, Zhenghang
    Lu, Xin'an
    He, Ting
    Ding, Yanping
    Wu, Fei
    Liu, Dongqun
    Shen, Lin
    MOLECULAR THERAPY, 2024, 32 (04) : 882 - 882
  • [35] Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer
    Qi, Changsong
    Liu, Chang
    Li, Jian
    Gong, Jifang
    Wang, Xicheng
    Wang, Zhenghang
    Lu, Xin-An
    He, Ting
    Ding, Yanping
    Wu, Fei
    Liu, Dongqun
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
    Kim, Ji-Hae
    Lee, Kun-Joo
    Lee, Seung-Woo
    BMB REPORTS, 2021, 54 (01) : 21 - 30
  • [37] Targeting Pim2 for Improving T-Cell Effector Function and Promoting Cancer Immunotherapy
    Wu, Yongxia
    Tian, Linlu
    Mealer, Corey
    Choi, Hee-Jin
    Yu, Xue-Zhong
    BLOOD, 2021, 138
  • [38] QL335, a novel T cell engager with enhanced safety profile targeting MSS colorectal cancer
    Gu, Shenda
    Guo, Guangjie
    Yee, Helena
    Tran, Hieu V.
    Chen, Shihao
    Cao, Chuanzeng
    Liu, Ke
    Jin, Chunyan
    Lun, Weihua
    Ma, Ruixue
    Ren, Lele
    CANCER RESEARCH, 2024, 84 (06)
  • [39] ET140202 T-cell therapy for the treatment of liver cancer is built upon a novel antibody-T cell receptor (AbTCR) ARTEMIS™ T-cell platform
    Cui, Jun
    Zhang, Pengbo
    Yun, Hongruo
    Xu, Yiyang
    Horan, Lucas
    Xu, Shaohua
    Xu, Sean
    Liu, Hong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [40] YYFZBJS ameliorates colorectal cancer progression in ApcMin/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation
    Hua Sui
    Lu Zhang
    Kaijuan Gu
    Ni Chai
    Qing Ji
    Lihong Zhou
    Yan Wang
    Junze Ren
    Limei Yang
    Bimeng Zhang
    Jing Hu
    Qi Li
    Cell Communication and Signaling, 18
12345